Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Stock picking tips

Fri, 06th Mar 2020 15:39

* Bourses fall in virus worries
* Europe's bank at lowest since 2009

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Thyagaraju Adinarayan
(thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus
(julien.ponthus@tr.com) in London.

STOCK PICKING TIPS (1540 GMT)
Here are some stock picking tip from BNP Paribas' Edmund Shing.
"You will find that stocks that are sensitive to bonds, relatively speaking are caught up
better than the market overall. Now the stocks that tend to be more bond sensitive are
defensive, and tend to be located in sectors like healthcare and utilities for instance," he
told us in an interview.
"That is often because they have lots of debt," he adds.
Shing also gives hints on how to pick the best stocks in the coronavirus era, beyond the big
utilities names.
"It's very difficult: One strategy you can employ is looking for companies that are falling
off," he says, if you don't find an explanation - like a profit warning or something
fundamentally wrong - this company may be your pick.
Smaller companies often suffer when there is a big sell-off, because in panic selling
investors rush to take some profits off the table, but "in fact the companies that suffer the
sharpest fall sometimes can be those which have very strong fundamentals, which explain why they
had such good performance before the crisis".
"When fundamentals and valuations are diverging, there is a chance that at some point the
price will shoot up, and prices at some point rejoins fundamentals".
(Joice Alves)
*****


WHAT A RIDE FOR UTILITIES! (1411 GMT)
The sector is losing some ground today, although it's still outperforming the others in the
daily coronavirus sell-off we've been seeing of late in Europe. Year-to-date it has been
a darling among investors surviving the meltdown in markets.


European utilities have delivered a double-digit return so far this year and there is more
to that than the bond yield, DB's James Brand writes. Here is his guess why:
- The turn in earnings cycle and return to growth
- Enthusiasm for ESG
- The coronavirus driven rotation into defensives
"Interestingly our correlation analysis suggests that this could be justified just by the
drop in bond yields. However, our view is that robust medium-term earnings growth and long-term
investment opportunities related to ESG may be better reasons to remain bullish," Brand adds.

(Joice Alves)
*****


CARNAGE! (1323 GMT)
Are markets losing it? Bear market territory is not too far away for many bourses. The
pan-European STOXX 600 index has now fallen close to 16% from record highs. Wall Street
meanwhile is getting ready for a 3.2% drop.
"We think that equities will need more visibility if they are to manage to build a viable
bottom or to be able to tap into the power afforded by a reasonable sense of relief – for
example, as a result of easing in the momentum of new coronavirus cases also outside China,"
Christian Stocker at UniCredit says.




(Thyagaraju Adinarayan)
*****

EUROPE'S BANKS AT LOWEST SINCE 2009 (1110 GMT)
European banks are down close to 4% and have now hit their lowest since 2009 as the
coronavirus scare cuts deeper into global markets.
We're past bear territory with a fall of about 25% since February.
Seems there's a combination of straight recession fears (with all that means in terms of
toxic NPLs quickly building up) and expectations of another ECB cut which would bite hard into
margins again.
Germany's 10-y govt bond yield fell to -0.740%, which is very, very close to its record low
of -0.743 of September 2019.
"The situation of the European banking sector is completely different from what it was in
2009", Jerome Legras, head of research at Axiom Alternative Investments just told us.
"There’s the psychological aspect of hitting the same level but I’m not more worried about
their solvency than I was three weeks ago", he added.
"Profitability is a different story though..."

Take a look:


(Joice Alves and Julien Ponthus)
*****



OPENING SNAPSHOT: NOT THE TIME FOR TRAVEL & LEISURE (0823 GMT)
European bourses open in negative territory as coronavirus fears continue to drag down the
stock market.
The pan European index is on track for its third straight day of declines and
needless to say the travel and leisure space is lagging behind all the other sectors,
down more than 3%.
In terms of single stocks, Italy's Prysmian started the day among the top movers,
down almost 10%, after it warned that core profit will not grow this year, blaming trade
tensions, higher tariffs and the coronavirus outbreak.
Capita's capitulation continues as brokers cut price targets after the company's
update yesterday sent shares down 40%.

(Joice Alves)
*****


STOCKS TO WATCH: INFINEON, AIRBUS, ESSILORLUXOTTICA (0745 GMT)
Futures point to another blow for European bourses with 2% plus declines across the board as
coronavirus anxiety continues to grip investors.
In the corporate world, Infineon in focus after a Bloomberg reported that
Washington recommended Trump to block the German chipmaker's proposed $10 billion deal to buy
Cypress Semiconductor as it poses a security risk.
Airbus shares could take a hit as it got zero orders for February due to
coronavirus, but worth remembering that the recent sell-off has likely priced-in most of the bad
news.
EssilorLuxottica is the other name to watch out for after the company said it
expects is first-half revenues to be slower (I'd let you guess the why here).
Non-virus news: British pharma AstraZeneca seen down 2% after its combination
treatment for a form of bladder cancer failed to meet the main goal.

(Thyagaraju Adinarayan)
*****


ANOTHER DAY, ANOTHER SELL-OFF (0637 GMT)
Stocks are seen opening sharply lower again today on top of yesterday's ugly sell-off that
took bank stocks into bear market territory along with autos, travel & leisure and oil & gas.
The number of global coronavirus cases is fast approaching the 100k mark with fears of a
massive economic damage sending shivers down investors' spine.
Financial spreadbetters IG expect London's FTSE to open 114 points lower at 6,592,
Frankfurt's DAX to open 255 points lower at 11,690 and Paris' CAC to open 116 points lower at
5,246.
"Markets have shifted from pricing temporary China weakness to a more protracted global
event, which will see a good chunk of global GDP go up in smoke," said Stephen Innes, chief
market strategist at AxiCorp.

(Thyagaraju Adinarayan)
*****





(Reporting by Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.